New hope for tough colorectal cancer: Triple-Drug combo enters human trials
NCT ID NCT07591597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—S-531011, fruquintinib, and pembrolizumab—in people with advanced colorectal cancer that has not responded to standard treatments. The cancer type is called MSS or pMMR, which typically does not respond well to immunotherapy alone. The trial has two parts: first, finding the safest dose, and then checking if the drug combo can shrink tumors. About 68 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- S-531011 (a lab-made antibody) plus fruquintinib (a targeted cancer pill), with or without pembrolizumab (an immunotherapy)
- What this could lead to
- If it works, this could offer a new treatment option for people with a hard-to-treat type of colorectal cancer that hasn't responded to standard therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 68 participants, so it's too small to prove effectiveness. The drug combo may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.